Day One Biopharmaceuticals (NASDAQ:DAWN) Given Outperform Rating at Wedbush

Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report)‘s stock had its “outperform” rating reissued by equities research analysts at Wedbush in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $32.00 price objective on the stock. Wedbush’s price objective suggests a potential upside of 238.98% from the company’s previous […]

Feb 28, 2025 - 08:57

Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report)‘s stock had its “outperform” rating reissued by equities research analysts at Wedbush in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $32.00 price objective on the stock. Wedbush’s price objective suggests a potential upside of 238.98% from the company’s previous […]